Zevra Therapeutics, Inc. $ZVRA Shares Sold by 683 Capital Management LLC

683 Capital Management LLC cut its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 7.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 905,000 shares of the company’s stock after selling 70,000 shares during the period. 683 Capital Management LLC’s holdings in Zevra Therapeutics were worth $8,109,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. boosted its position in shares of Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after buying an additional 4,475 shares during the period. Tower Research Capital LLC TRC lifted its position in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the period. Creative Planning acquired a new stake in Zevra Therapeutics in the second quarter worth approximately $92,000. Qube Research & Technologies Ltd acquired a new stake in Zevra Therapeutics in the second quarter worth approximately $99,000. Finally, Quarry LP acquired a new stake in Zevra Therapeutics in the third quarter worth approximately $103,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZVRA. Wall Street Zen downgraded Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Canaccord Genuity Group upped their target price on Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Guggenheim upped their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Citizens Jmp upped their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 9th. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, June 9th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $29.29.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $12.61 on Thursday. The stock has a market capitalization of $745.50 million, a P/E ratio of 6.34 and a beta of 0.91. Zevra Therapeutics, Inc. has a 1 year low of $7.16 and a 1 year high of $14.27. The business’s fifty day moving average is $10.88 and its two-hundred day moving average is $9.59.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.12. The company had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. On average, research analysts forecast that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.